TY - JOUR
T1 - MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer
AU - Yasumizu, Yota
AU - Rajabi, Hasan
AU - Jin, Caining
AU - Hata, Tsuyoshi
AU - Pitroda, Sean
AU - Long, Mark D.
AU - Hagiwara, Masayuki
AU - Li, Wei
AU - Hu, Qiang
AU - Liu, Song
AU - Yamashita, Nami
AU - Fushimi, Atsushi
AU - Kui, Ling
AU - Samur, Mehmet
AU - Yamamoto, Masaaki
AU - Zhang, Yan
AU - Zhang, Ning
AU - Hong, Deli
AU - Maeda, Takahiro
AU - Kosaka, Takeo
AU - Wong, Kwok K.
AU - Oya, Mototsugu
AU - Kufe, Donald
N1 - Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective targeted therapies. The oncogenic MUC1-C protein is overexpressed in castration-resistant prostate cancer (CRPC) and NEPC, but its specific role is unknown. Here, we demonstrate that upregulation of MUC1-C in androgen-dependent PC cells suppresses androgen receptor (AR) axis signaling and induces the neural BRN2 transcription factor. MUC1-C activates a MYC→BRN2 pathway in association with induction of MYCN, EZH2 and NE differentiation markers (ASCL1, AURKA and SYP) linked to NEPC progression. Moreover, MUC1-C suppresses the p53 pathway, induces the Yamanaka pluripotency factors (OCT4, SOX2, KLF4 and MYC) and drives stemness. Targeting MUC1-C decreases PC self-renewal capacity and tumorigenicity, suggesting a potential therapeutic approach for CRPC and NEPC. In PC tissues, MUC1 expression associates with suppression of AR signaling and increases in BRN2 expression and NEPC score. These results highlight MUC1-C as a master effector of lineage plasticity driving progression to NEPC.
AB - Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective targeted therapies. The oncogenic MUC1-C protein is overexpressed in castration-resistant prostate cancer (CRPC) and NEPC, but its specific role is unknown. Here, we demonstrate that upregulation of MUC1-C in androgen-dependent PC cells suppresses androgen receptor (AR) axis signaling and induces the neural BRN2 transcription factor. MUC1-C activates a MYC→BRN2 pathway in association with induction of MYCN, EZH2 and NE differentiation markers (ASCL1, AURKA and SYP) linked to NEPC progression. Moreover, MUC1-C suppresses the p53 pathway, induces the Yamanaka pluripotency factors (OCT4, SOX2, KLF4 and MYC) and drives stemness. Targeting MUC1-C decreases PC self-renewal capacity and tumorigenicity, suggesting a potential therapeutic approach for CRPC and NEPC. In PC tissues, MUC1 expression associates with suppression of AR signaling and increases in BRN2 expression and NEPC score. These results highlight MUC1-C as a master effector of lineage plasticity driving progression to NEPC.
UR - http://www.scopus.com/inward/record.url?scp=85078010842&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078010842&partnerID=8YFLogxK
U2 - 10.1038/s41467-019-14219-6
DO - 10.1038/s41467-019-14219-6
M3 - Article
C2 - 31953400
AN - SCOPUS:85078010842
SN - 2041-1723
VL - 11
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 338
ER -